Jay Engelberg

Dr. Edelberg is a clinical cardiologist and vascular biologist, having served in leadership roles for two decades in both academic medicine and the biopharmaceutical industry. Most recently, Dr. Edelberg led cardiovascular drug development at Sanofi, where he spearheaded the development of Praluent® and oversaw the clinical development and global project teams involved in the MyoKardia partnership. Previously, Dr. Edelberg directed cardiovascular biomarker research at Bristol-Myers Squibb, where he served as the U.S. medical lead for Eliquis® and at Glaxo SmithKline.

From 1999 to 2006, Dr. Edelberg served as an attending coronary care unit (CCU) cardiologist and directed the Cardiac Vascular Biology Research Laboratory at Weill-Cornell Medical Center, with a specific research focus on cardiac stems cells and biomarkers of cardiac aging. Dr. Edelberg trained at the Massachusetts General Hospital (Internal Medicine), the Beth Israel Deaconess Medical Center in Boston (Cardiovascular Medicine) and Massachusetts Institute of Technology (Biology). Dr. Edelberg is an M.D., Ph.D., graduate of Duke University in Durham, North Carolina.